Pek 10 vial6 stokJimat 25%Retatrutide 30 mg
Peptida penyelidikan tri-agonis GLP-1 / GIP / glukagon
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Untuk tujuan penyelidikan sahaja. Sebatian ini dijual secara ketat untuk penyelidikan in-vitro dan tujuan makmal, dan tidak dimaksudkan untuk kegunaan manusia atau penggunaan terapeutik. Dengan membeli, anda mengesahkan bahawa anda ialah penyelidik yang berkelayakan dan bersetuju dengan penafian penuh kami.
Tinggal 6 pek sahaja
Peptida penyelidikan agonis tiga reseptor yang dikaji untuk kesan gabungan pada laluan isyarat GLP-1, GIP, dan glukagon dalam aplikasi penyelidikan metabolik.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mekanisme
Dikaji untuk agonisme serentak reseptor GLP-1, GIP, dan glukagon. Penyelidikan dikaitkan dengan penanda kadar metabolisme, rasa kenyang, dan perbelanjaan tenaga dalam populasi kajian.
Disahkan HPLC terhadap spesifikasi ketulenan ≥99%. Diuji secara bebas oleh makmal pihak ketiga bertauliah.
Retatrutide — soalan lazim
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Panduan berkaitan Retatrutide
Penyelidik juga meneliti
Pek 10 vialJimat 22%MOTS-c
Serbuk liofilisasi10 mg · 2 strengths
Peptida metabolik terbitan mitokondria
Dalam 2 gabungan
Pek 10 vialJimat 17%5-Amino-1MQ
Serbuk liofilisasi50 mg · 3 strengths
Sebatian penyelidikan perencat NNMT
Pek 10 vialJimat 15%L-Carnitine
Sterile solution10 ml × 600 mg/ml
Pengangkut asid lemak mitokondria
Dalam 1 gabungan